Skip to main content
Caplight Logo









Epitopea

Epitopea

Private
CambridgeHealthcare & Life Scienceshttps://www.epitopea.com/

Last Round

VC Round

Oct 24, 2024

Total Funding Raised

$14.26M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Epitopea is a biotechnology company developing off-the-shelf RNA-based cancer immunotherapies that target a novel class of tumor-specific antigens.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Application

Keywords

cancer immunotherapyRNA immunotherapycancer vaccineoff-the-shelf therapyantigen discoveryshared tumor antigenstumor-specific antigenshidden antigensoncology biotechpharma licensingTSA discoveryjunk DNA targetscold tumor therapycomputational biology platformnucleic acid deliverynon-coding DNA discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Epitopea Comparables

Compare Epitopea with similar companies based on industry and business-model similarity.

Epitopea comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Enara Bio
84%
Hervolution Therapeutics
81%
Cartography Biosciences
80%

Epitopea Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundOct 24, 2024
GrantSep 12, 2024
SeedApr 25, 2022

Epitopea Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors increased 47% MoM, reaching 3.1K.

  • Apr 23, 2026

    Susana Banerjee appointed Chief Investigator for OVACT trial.

Epitopea Filings

Explore SEC and related filing metadata, where available.

Epitopea filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Epitopea's valuation, stock price, and market status.

Is Epitopea a public or private company?

Epitopea is a private company.

What is the current stock price of Epitopea?

Epitopea is a private company with no public stock price. No recent secondary market data is available.

How much is Epitopea worth (valuation)?

Valuation information for Epitopea is not publicly available.

Can I buy Epitopea stock?

Epitopea shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Epitopea's last funding round?

Epitopea's most recent funding round was Pre Seed on October 24, 2024.

Who are the main investors in Epitopea?

Key investors in Epitopea include Investissement Québec, Advent Life Sciences, adMare BioInnovations.

Will Epitopea IPO soon?

No public IPO plans have been announced for Epitopea.

How can I track Epitopea secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Epitopea's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge
Employee Range43
Year Founded2021
Last FundingOct 24, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?